Journal of Diabetes and Its Complications
Volume 19, Issue 3 , Pages 168-177 , May 2005

Thiazolidinediones—Benefits on microvascular complications of type 2 diabetes

  • Giancarlo Viberti

      Affiliations

    • Corresponding Author InformationUnit for Metabolic Medicine, 5th Floor, Thomas Guy House, KCL Guy's Hospital, London SE1 9RT, UK. Tel.: +44-20-7955-4826; fax: +44-20-7955-2985

Received 5 November 2003 ,Revised 6 January 2004 ,Accepted 5 April 2004.

References 

  1. American Diabetes Association . Standards of medical care for patients with diabetes mellitus. Diabetes Care. 2003;26(Suppl. 1):S33–S50
  2. Arner P. The adipocyte in insulin resistance: key molecules and the impact of the thiazolidinediones. Trends in Endocrinology and Metabolism. 2003;14:137–145
  3. Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose–response study. The Pioglitazone 001 Study Group. Diabetes Care. 2000;23:1605–1611
  4. Bakris G, Viberti G, Weston W, Heise M, Porter LE, Freed MI. Rosiglitazone reduces urinary albumin excretion in type 2 diabetes. Journal of Human Hypertension. 2003;17:7–12
  5. Barnett AH. Insulin-sensitizing agents—Thiazolidinediones (glitazones). Current Medical Research and Opinion. 2002;18(Suppl. 1):S31–S39
  6. Bishop-Bailey D, Hla T. Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-Delta12, 14-prostaglandin J2. Journal of Biological Chemistry. 1999;274:17042–17048
  7. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813–820
  8. Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes. 2002;51:2796–2803
  9. Buse JB, Gumbiner B, Mathias NP, Nelson DM, Faja BW, Whitcomb RW. Troglitazone use in insulin-treated type 2 diabetic patients. The Troglitazone Insulin Study Group. Diabetes Care. 1998;21:1455–1461
  10. Carey DG, Cowin GJ, Galloway GJ, Jones NP, Richards JC, Biswas N, et al. Sensitivity effect of rosiglitazone on insulin and body composition in type 2 diabetic patients. Obesity Research. 2002;10:1008–1015
  11. Charbonnel B, Lonnqvist F, Jones NP, Abel MG, Patwardhan R. Rosiglitazone is superior to glyburide in reducing fasting plasma glucose after 1 year of treatment in type 2 diabetic patients. Diabetes. 1999;48(Suppl. 1):A114–A115
  12. Chen J, Gall MA, Yokoyama H, Jensen JS, Deckert M, Parving HH. Raised serum sialic acid concentration in NIDDM patients with and without diabetic nephropathy. Diabetes Care. 1996;19:130–134
  13. Chu NV, Kong AP, Kim DD, Armstrong D, Baxi S, Deutsch R, et al. Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes. Diabetes Care. 2002;25:542–549
  14. Diabetes Control and Complications Trial Research Group . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New England Journal of Medicine. 1993;329:977–986
  15. Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. Archives of Internal Medicine. 1997;157:1413–1418
  16. Dyck PJ, Kratz KM, Karnes JL, Litchy WJ, Klein R, Pach JM, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology. 1993;43:817–824
  17. Earle KA, Morocutti A, Viberti G. Permissive role of hypertension in the development of proteinuria and progression of renal disease in insulin-dependent diabetic patients. Journal of Hypertension. 1997;15:191–196
  18. Einhorn D, Rendell M, Rosenzweig J, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group. Clinical Therapeutics. 2000;22:1395–1409
  19. Emoto M, Anno T, Sato Y, Tanabe K, Okuya S, Tanizawa Y, et al. Troglitazone treatment increases plasma vascular endothelial growth factor in diabetic patients and its mRNA in 3T3-L1 adipocytes. Diabetes. 2001;50:1166–1170
  20. European Diabetes Policy Group . A desktop guide to type 2 diabetes. Diabetic Medicine. 1999;16:716–730
  21. Fong DS, Aiello L, Gardner TW, King GL, Blankenship G, Cavallerano JD, et al. Diabetic retinopathy. Diabetes Care. 2003;26(Suppl. 1):S99–S102
  22. Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. Journal of the American Medical Association. 2000;283:S1695–S1702
  23. Freed M, Fuell D, Menci L, Heise M, Goldstein B. Effect of combination therapy with rosiglitazone and glibenclamide on PAI-1 antigen, PAI-1 activity and tPA in patients with type 2 diabetes. Diabetologia. 2000;43(Suppl. 1):A267
  24. Freed MI, Ratner R, Marcovina SM, Kreider MM, Biswas N, Cohen BR, et al. Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. American Journal of Cardiology. 2002;90:947–952
  25. Fullert S, Schneider F, Haak E, Rau H, Badenhoop K, Lubben G, et al. Effects of pioglitazone in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study. Journal of Clinical Endocrinology and Metabolism. 2002;87:5503–5506
  26. Gnudi L, Viberti G, Raij L, Rodriguez V, Burt D, Cortes P, et al. GLUT-1 overexpression: link between hemodynamic and metabolic factors in glomerular injury?. Hypertension. 2003;1:19–24
  27. Haffner S, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation. 2002;106:679–684
  28. Horton ES, Whitehouse F, Ghazzi MN, Venable TC, Whitcomb RW. Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes. The Troglitazone Study Group. Diabetes Care. 1998;21:1462–1469
  29. Inzucchi SE, Maggs DG, Spollett GR, Page SL, Rife FS, Walton V, et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. New England Journal of Medicine. 1998;338:867–872
  30. Jariwala S, Mather R, Walker L, Nadra AR, Leigh P. Long term glycaemic control with rosiglitazone in combination with metformin (Abstract). Diabetic Medicine. 2003; April
  31. Jarrett RJ, Viberti GC, Argyropoulos A, Hill RD, Mahmud U, Murrells TJ. Microalbuminuria predicts mortality in non-insulin-dependent diabetics. Diabetic Medicine. 1984;1:17–19
  32. King AB. A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones. Diabetes Care. 2000;23:557
  33. Kipnes MS, Krosnick A, Rendell MS, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. American Journal of Medicine. 2001;111:10–17
  34. Kreider M, Miller E, Patel J. Rosiglitazone is safe and well tolerated as monotherapy or combination therapy in patients with type 2 diabetes mellitus (T2DM). Diabetes. 1999;48(Suppl. 1):A117
  35. Kubo K. Effect of pioglitazone on blood proinsulin levels in patients with type 2 diabetes mellitus. Endocrine Journal. 2002;49:323–328
  36. Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. Journal of Clinical Endocrinology and Metabolism. 2001;86:280–288
  37. Lebovitz HE, Kreider M, Freed MI. Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction. Diabetes Care. 2002;25:815–821
  38. Martens FM, Visseren FL, Lemay J, de Koning EJ, Rabelink TJ. Metabolic and additional vascular effects of thiazolidinediones. Drugs. 2002;62:1463–1480
  39. Matthews DR, Bakst AW, Weston WM, Hemyari P. Rosiglitazone decreases insulin resistance and improves beta-cell function in patients with type 2 diabetes. Diabetologia. 1999;42(Suppl. 1):A228
  40. Mattock MB, Barnes DJ, Viberti G, Keen H, Burt D, Hughes JM, et al. Microalbuminuria and coronary heart disease in NIDDM: an incidence study. Diabetes. 1998;47:1786–1792
  41. Mayerson AB, Hundal RS, Dufour S, Lebon V, Befroy D, Cline GW, et al. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes. 2002;51:797–802
  42. Mayfield JA, Reiber GE, Sanders LJ, Janisse D, Pogach LM. Preventive foot care in people with diabetes. Diabetes Care. 2003;26(Suppl. 1):S78–S79
  43. Miettinen H, Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Proteinuria predicts stroke and other atherosclerotic vascular disease events in nondiabetic and non-insulin-dependent diabetic subjects. Stroke. 1996;27:2033–2039
  44. Miyazaki Y, Glass L, Triplitt C, Matsuda M, Cusi K, Mahankali A, et al. Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in type II diabetic patients. Diabetologia. 2001;44:2210–2219
  45. Miyazaki Y, Mahankali A, Matsuda M, Glass L, Mahankali S, Ferrannini E, et al. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care. 2001;24:710–719
  46. Molitch ME, DeFronzo RA, Franz MJ, Keane WF, Mogensen CE, Parving HH. Diabetic nephropathy. Diabetes Care. 2003;26(Suppl. 1):S94–S98
  47. Murata T, Hata Y, lshibashi T, Kim S, Hsueh WA, Law RE, et al. Response of experimental retinal neovascularization to thiazolidinediones. Archives of Ophthalmology. 2001;119:709–717
  48. Murata T, He S, Hangai M, lshibashi T, Xi XP, Kim S, et al. Peroxisome proliferator-activated receptor-gamma ligands inhibit choroidal neovascularization. Investigative Ophthalmology and Visual Science. 2000;41:2309–2317
  49. Nakamura T, Ushiyama C, Osada S, Hara M, Shimada N, Koide H. Pioglitazone reduces urinary podocyte excretion in type 2 diabetes patients with microalbuminuria. Metabolism. 2001;50:1193–1196
  50. Natali A, Baldeweg S, Toschi E, Barbaro D, Capaldo B, Yudkin J, et al. Rosiglitazone directly improves endothelial function in type 2 diabetic patients. Diabetes. 2002;51(Suppl. 2):A142
  51. National Institute for Clinical Excellence . Clinical guideline G. Management of type 2 diabetes: management of blood glucose. London: National Institute for Clinical Excellence; 2002;
  52. National Institute for Clinical Excellence . Clinical guideline E. Management of type 2 diabetes: retinopathy—Screening and early management. London: National Institute for Clinical Excellence; 2002;
  53. National Institute for Clinical Excellence . Clinical guideline E. Management of type 2 diabetes: renal disease—Prevention and early management. London: National Institute for Clinical Excellence; 2002;
  54. Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation. 2003;108:2941–2948
  55. Raji A, Seely EW, Bekins SA, Williams GH, Simonson DC. Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care. 2003;26:172–178
  56. Raptis AE, Viberti G. Pathogenesis of diabetic nephropathy. Experimental and Clinical Endocrinology and Diabetes. 2001;109(Suppl. 2):S424–S437
  57. Raskin P, Rendell M, Riddle MC, Dole JF, Freed MI, Rosenstock J. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care. 2001;24:1226–1232
  58. Ravid M, Savin H, Jutrin I, Bental T, Lang R, Lishner M. Long-term effect of ACE inhibition on development of nephropathy in diabetes mellitus type II. Kidney International Supplement. 1994;45:S161–S164
  59. Rosenstock J, Einhorn D, Hershon K, Glazer NB, Yu S. Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy. International Journal of Clinical Practice. 2002;56:251–257
  60. Rowley K, O'Dea K, Best JD. Association of albuminuria and the metabolic syndrome. Current Diabetes Reports. 2003;3:80–86
  61. Savage S, Estacio RO, Jeffers B, Schrier RW. Urinary albumin excretion as a predictor of diabetic retinopathy, neuropathy, and cardiovascular disease in NIDDM. Diabetes Care. 1996;19:1243–1248
  62. Sheetz MJ, King GL. Molecular understanding of hyperglycemia's adverse effects for diabetic complications. Journal of the American Medical Association. 2002;288:2579–2588
  63. Sima AA, Thomas PK, Ishii D, Vinik A. Diabetic neuropathies. Diabetologia. 1997;40(Suppl. 3):B74–B77
  64. Spranger J, Pfeiffer AF. New concepts in pathogenesis and treatment of diabetic retinopathy. Experimental and Clinical Endocrinology and Diabetes. 2001;109(Suppl. 2):S438–S450
  65. St John Sutton M, Rendell M, Dandona P, Dole JF, Murphy K, Patwardhan R, et al. A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes mellitus. Diabetes Care. 2002;25:2058–2064
  66. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. British Medical Journal. 2000;321:405–412
  67. Tooke J. The association between insulin resistance and endotheliopathy. Diabetes, Obesity and Metabolism. 1999;1(Suppl. 1):S17–S22
  68. Tooke JE, Goh KL. Vascular function in type 2 diabetes mellitus and pre-diabetes: the case for intrinsic endotheliopathy. Diabetic Medicine. 1999;16:710–715
  69. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. Journal of the American Medical Association. 1999;281:2005–2012
  70. UK Prospective Diabetes Study (UKPDS) Group . VIII. Study design, progress and performance. Diabetologia. 1991;34:877–890
  71. UK Prospective Diabetes Study (UKPDS) Group . UK prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes. 1995;44:1249–1258
  72. UK Prospective Diabetes Study (UKPDS) Group . Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853
  73. UK Prospective Diabetes Study (UKPDS) Group . Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. British Medical Journal. 1998;317:703–713
  74. UK Prospective Diabetes Study (UKPDS) Group . Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. British Medical Journal. 1998;317:713–720
  75. Viberti G. Prognostic significance of microalbuminuria. American Journal of Hypertension. 1994;7:S69–S72
  76. Viberti, G., Freed, M. I., Holman, R., Lachin, J., & Heise, M. A. (2003). Prevalence of microalbuminuria and its relationship to non-traditional risk factors in recently diagnosed type 2 diabetes mellitus: observations from the ADOPT study. Abstract from American Diabetes Association Annual Meeting, 2003.
  77. Viberti G, Kahn SE, Greene DA, Herman WH, Zinman B, Holman RR, et al. A Diabetes Outcome Progression Trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care. 2002;25:1737–1743
  78. Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation. 2002;106:672–678
  79. Viberti GC. Rosiglitazone: potential beneficial impact on cardiovascular disease. International Journal of Clinical Practice. 2003;57:128–134
  80. Vinik AI, Erbas T, Stansberry KB, Pittenger GL. Small fiber neuropathy and neurovascular disturbances in diabetes mellitus. Experimental and Clinical Endocrinology and Diabetes. 2001;109(Suppl. 2):S451–S473
  81. Wolffenbuttel BH, Gomis R, Squatrito S, Jones NP, Patwardhan RN. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in type 2 diabetic patients. Diabetic Medicine. 2000;17:40–47
  82. Xin X, Yang S, Kowalski J, Gerritsen ME. Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo. Journal of Biological Chemistry. 1999;274:9116–9121
  83. Yamasaki Y, Kawamori R, Wasada T, Sato A, Omori Y, Eguchi H, et al. Pioglitazone (AD-4833) ameliorates insulin resistance in patients with NIDDM. AD-4833 Glucose Clamp Study Group, Japan. Tohoku Journal of Experimental Medicine. 1997;183:173–183
  84. Zinman B. PPAR gamma agonists in type 2 diabetes: how far have we come in “preventing the inevitable”? A review of the metabolic effects of rosiglitazone. Diabetes, Obesity and Metabolism. 2001;3(Suppl. 1):S34–S43

PII: S1056-8727(04)00035-2

doi: 10.1016/j.jdiacomp.2004.04.001

Journal of Diabetes and Its Complications
Volume 19, Issue 3 , Pages 168-177 , May 2005

Article Tools

* Image Usage & Resolution